Teva Neuroscience, Inc.: Study Showed Patients Using COPAXONE® Had Significantly Lower Risk of Relapse and Lower Medical Costs Compared to Patients Using Rebif® in Relapsing-Remitting Multiple Sclerosis (RRMS)

KANSAS CITY, Mo.--(BUSINESS WIRE)--A retrospective study comparing outcomes of relapsing-remitting multiple sclerosis (RRMS) patients treated either with COPAXONE® (glatiramer acetate injection) or high-dose interferon beta-1a (Rebif®)demonstrated that patients continuously treated with COPAXONE® had a significantly lower risk of relapse (p=0.0049) and experienced significantly lower two-year total medical costs (p<0.0001) than those continuously treated with interferon beta-1a (Rebif®).